See related Rocaltrol cap information |
|
Manufacturer |
Roche |
Distributor |
DKSH |
Contents |
Calcitriol |
Indications |
Postmenopausal osteoporosis, renal osteodystrophy in patients w/ chronic renal failure esp those undergoing hemodialysis. Post-surgical, idiopathic hyperparathyroidism, pseudohypoparathyroidism, vit D dependency rickets. Hypophosphatemic vit D-resistant rickets. |
Dosage |
Postmenopausal osteoporosis 0.25 mcg bid. May increase at mthly intervals to 0.5 mcg bid. Renal osteodystrophy in dialysis patients Initially 0.25 mcg/day. Patients w/ normal or slightly reduced serum Ca: 0.25 mcg every other day. Dosage may be increased by 0.75 mcg/day at 2-4 wk intervals to a usual dosage of 0.5-1 mcg/day. Hyperparathyroidism & rickets Initially 0.25 mcg in the morning. May increase at 2-4 wk intervals. |
Administration |
May be taken with or without food (May be taken w/ meals to reduce GI discomfort.). |
Contraindications |
Hypercalcemia. Vit D-containing prep. |
Special Precautions |
Infants. Lactation. |
Adverse Drug Reactions |
Hypercalcemia syndrome; Ca intoxication.
View ADR Monitoring Form |
Drug Interactions |
Mg-containing drugs. Phosphate-binding agents (adjust dosage).
View more drug interactions with Rocaltrol |
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
Presentation/Packing |
Form |
Packing |
Photo |
Rocaltrol capsule |
Rocaltrol 0.25 mcg x 100's |
 |
|
|
Manufacturer: |
Roche |
Distributor: |
DKSH
|
|
|
|